Ally Bridge Group NY LLC Acquires New Stake in Dianthus Therapeutics, Inc. (NASDAQ:DNTH)

Ally Bridge Group NY LLC acquired a new stake in Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund acquired 106,434 shares of the company's stock, valued at approximately $2,320,000. Dianthus Therapeutics comprises approximately 1.9% of Ally Bridge Group NY LLC's investment portfolio, making the stock its 25th biggest position. Ally Bridge Group NY LLC owned 0.36% of Dianthus Therapeutics at the end of the most recent quarter.

Other large investors have also added to or reduced their stakes in the company. R Squared Ltd purchased a new stake in Dianthus Therapeutics in the fourth quarter worth $26,000. KLP Kapitalforvaltning AS bought a new stake in shares of Dianthus Therapeutics during the 4th quarter valued at about $33,000. KBC Group NV purchased a new stake in Dianthus Therapeutics in the fourth quarter worth about $35,000. AlphaQuest LLC boosted its position in Dianthus Therapeutics by 273.1% during the 4th quarter. AlphaQuest LLC now owns 4,197 shares of the company's stock valued at $91,000 after acquiring an additional 3,072 shares in the last quarter. Finally, Intech Investment Management LLC purchased a new position in shares of Dianthus Therapeutics during the 4th quarter worth approximately $201,000. Institutional investors own 47.53% of the company's stock.

Dianthus Therapeutics Stock Down 0.7 %

NASDAQ:DNTH traded down $0.15 during midday trading on Monday, hitting $21.55. The stock had a trading volume of 176,971 shares, compared to its average volume of 264,198. The stock has a 50-day moving average of $19.85 and a 200 day moving average of $22.64. The company has a market capitalization of $692.32 million, a price-to-earnings ratio of -8.62 and a beta of 1.48. Dianthus Therapeutics, Inc. has a one year low of $13.37 and a one year high of $32.27.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last posted its earnings results on Tuesday, March 11th. The company reported ($0.81) EPS for the quarter, beating analysts' consensus estimates of ($0.85) by $0.04. Dianthus Therapeutics had a negative net margin of 1,250.32% and a negative return on equity of 21.68%. The company had revenue of $1.33 million during the quarter, compared to analysts' expectations of $1.40 million. On average, sell-side analysts anticipate that Dianthus Therapeutics, Inc. will post -2.61 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of analysts have recently weighed in on DNTH shares. Wedbush reaffirmed an "outperform" rating and issued a $36.00 target price on shares of Dianthus Therapeutics in a research report on Wednesday, March 12th. HC Wainwright reissued a "buy" rating and issued a $40.00 price target on shares of Dianthus Therapeutics in a research report on Wednesday, March 12th. Finally, Guggenheim reaffirmed a "buy" rating and set a $84.00 price objective on shares of Dianthus Therapeutics in a research report on Wednesday, March 12th. Seven equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Buy" and a consensus price target of $54.33.

Dianthus Therapeutics Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.